Immix Biopharma Inc./$IMMX
Immix Biopharma shares rise after its NXC-201 45-patient trial results were selected for an oral presentation at the ASH meeting.
23 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
- Ticker
- $IMMX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Los Angeles, United States
- Website
- www.immixbio.com
IMMX Metrics
BasicAdvanced
$668M
-
-$0.83
0.11
-
Price and volume
Market cap
$668M
Beta
0.11
52-week high
$15.10
52-week low
$2.89
Average daily volume
1.5M
Financial strength
Current ratio
25.134
Quick ratio
24.953
Long term debt to equity
0.004
Total debt to equity
0.004
Profitability
EBITDA (TTM)
-41.484
Effective tax rate (TTM)
-0.08%
Management effectiveness
Return on assets (TTM)
-20.52%
Return on equity (TTM)
-34.18%
Valuation
Price to book
2.52
Price to tangible book (TTM)
2.52
Price to free cash flow (TTM)
-9.864
Free cash flow yield (TTM)
-10.14%
Free cash flow per share (TTM)
-0.817
Growth
Earnings per share change (TTM)
7.06%
3-year earnings per share growth (CAGR)
1.31%
What the Analysts think about IMMX
Analyst ratings (Buy, Hold, Sell) for Immix Biopharma Inc. stock.
Analyst projections of the future price of Immix Biopharma Inc. stock.
Bulls say / Bears say
NXC-201 produced complete responses in 40 of 45 patients in the Phase 2 NEXICART-2 update. All 25 newly reported patients were either in complete response or MRD-negative, giving the treatment a strong efficacy signal. (IMMIX Biopharma)
The company reported no relapses so far among patients who reached complete response or MRD-negativity, and no neurotoxicity or enterocolitis. That combination of early durability and tolerability could matter in a seriously ill patient group. (IMMIX Biopharma)
Immix raised about $117 million net from its September share offering, providing substantial funding for NXC-201 development and other company needs. This reduces near-term pressure to finance the programme while it advances towards a filing. (IMMIX Biopharma)
The company now plans the final NEXICART-2 readout and a BLA submission for mid-2027. That leaves a lengthy period for execution and regulatory risk before the treatment could reach the market. (IMMIX Biopharma)
The September financing added 11.36 million new shares, diluting existing holders even as it strengthened the balance sheet. Further funding needs could bring more dilution if development or launch costs rise. (IMMIX Biopharma)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
IMMX Financial Performance
Revenues and expenses
IMMX Earnings Performance
Company profitability
Upcoming events
No upcoming events
IMMX News
AllArticlesVideos
Funds containing IMMX
Fund name | Fund size | $IMMX weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.